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Abstract 
The cardiovascular disease (CVD) risk factor, low density lipoprotein cholesterol (LDL-C)
increases with age, up until the midpoint of life in males and females. However, LDL-C can
decrease with age in older men and women. Intriguingly,  a recent systematic review also
revealed an inverse association between LDL-C levels and cardiovascular mortality in older
people; low levels of LDL-C were associated with reduced risk of mortality. Such findings
are puzzling and require a biological explanation. In this paper a hypothesis is proposed to
explain these observations.  We hypothesize that the free radical theory of ageing (FRTA)
together with disrupted cholesterol homeostasis can account for these observations. Based on
this hypothesis, dysregulated hepatic cholesterol homeostasis in older people is characterised
by two distinct metabolic states. The first state accounts for an older person who has elevated
plasma LDL-C. This state is underpinned by the FRTA which suggests there is a decrease in
cellular  antioxidant  capacity  with  age.  This  deficiency enables  hepatic  reactive  oxidative
species (ROS) to induce the total activation of HMG-CoA reductase, the key rate limiting
enzyme  in  cholesterol  biosynthesis.  An  increase  in  cholesterol  synthesis  elicits  a
corresponding rise  in  LDL-C,  due to  the  downregulation of  LDL receptor  synthesis,  and
increased production of very low density lipoprotein cholesterol (VLDL-C). In the second
state  of  dysregulation,  ROS  also  trigger  the  total  activation  of  HMG-CoA reductase.
However, due to an age associated decrease in the activity of cholesterol-esterifying enzyme,
acyl CoA: cholesterol acyltransferase, there is restricted conversion of excess free cholesterol
(FC) to  cholesterol  esters.  Consequently,  the  secretion  of  VLDL-C drops,  and there  is  a
corresponding  decrease  in  LDL-C.  As  intracellular  levels  of  FC  accumulate,  this  state
progresses to a pathophysiological condition akin to nonalcoholic fatty liver disease. It is our
conjecture  this  deleterious  state  has  the  potential  to  account  for  the  inverse  association
between LDL-C level and CVD risk observed in older people.
Introduction 
Cholesterol  is  an  essential  macronutrient  which  plays  an  indispensable  role  in  the  body.
Despite its metabolic utility, plasma cholesterol, particularly elevated levels of low density
lipoprotein  cholesterol  (LDL-C)  has  a  long  established  relationship  with  cardiovascular
morbidity and mortality  (1-4). The standing LDL-C has as a risk factor for cardiovascular
health is further emphasized by epidemiological studies which have shown LDL-C increases
up until the midpoint of life in males and females (5, 6). Conversely, as illustrated in figure 1
it has also been observed in population studies that LDL-C gradually decreases in the latter
decades of life  (5, 6). Why LDL-C increases with age until the midpoint of life and then
declines remains unknown. It  has been proposed, the rise  up until  midlife is driven by a
combination of intrinsic alterations to whole-body cholesterol metabolism, rather than any
single biological change (7). An equally intriguing question centres on a remarkable study of
the oldest old (those ≥ 85 years), where it was observed that both high and low levels of
LDL-C had a similar impact on mortality risk  (8). Interestingly, this finding arose despite
cardiovascular  disease  (CVD)  being  the  primary  cause  of  mortality  in  this  group.  This
anomaly was further underscored recently by a somewhat controversial systematic review,
which identified two cohorts of older people where CVD mortality was highest in the lowest
LDL-C quartile (9).
The studies  outlined above raise  the  possibility  of  elevated LDL-C diminishing,  or even
ceasing to be a significant risk factor for CVD mortality in older people. This contradiction is
perplexing, as elevated LDL-C is a core component of a paradigm which has been formulated
to account for the etiology of atherosclerotic-CVD (10). Traditionally, this model was based
on the premise that LDL-C, particularly when elevated accumulated within the innermost
layer of the artery wall  (11). However, the paradigm has evolved and it is now generally
accepted that atherosclerosis is an inflammatory process (12). Atherosclerosis comprises both
innate and adaptive immunity, and is advanced by lipid accumulation (13). The evolution of
this pernicious state involves elevated levels of LDL-C promoting atherosclerosis by binding
with  proteoglycans  in  the  intima  (14).  Once  LDL is  established  within  the  intima,  it
undergoes several stages of oxidative modification  (15). Oxidized lipids and oxidized-LDL
trigger  an  innate  immune  response  eventually  culminating  in  the  formation  of  an
atherosclerotic plaque, the defining clinical feature of atherosclerosis (10, 16). Thus, elevated
LDL-C is firmly established within the widely accepted model which accounts for the onset
of atherosclerotic-CVD. However, an explanation which accounts for the findings that LDL-
C diminishes as a risk factor for CVD in certain older people remains to be fully defined. To
address this gap in what is known about cholesterol metabolism, this paper will present a
hypothesis  which  attempts  to  explain  this  anomaly.  Our  idea  is  based  on  intracellular
cholesterol homeostasis, and its proposed intersection with the free radical theory of ageing.
The hypothesis accounts for 1) an increase in LDL-C with age 2) the converse scenario where
LDL-C decreases in older people 3) the finding that an inverse relationship exists between
cardiovascular mortality and LDL-C in certain older people.  
Premise of hypothesis
The paradoxical finding that an inverse relationship exists between the risk of cardiovascular
mortality and LDL-C in certain older people is thought provoking. Therefore, it is logical to
seek  a  reasonable  biological  explanation  for  this  conundrum.  To  address  the  problem,  a
worthwhile starting point is the well-established paradigm which accounts for the regulation
of plasma LDL-C levels. LDL is the final product of a metabolic cascade which begins with
the hepatic flux of very low density lipoproteins (VLDLs) from the liver to the plasma (17).
During this process the majority of cholesterol re-enters the liver due to the uptake of VLDL
and LDL  (17). LDL-C is removed from the circulation by receptor mediated endocytosis
(18). The arbiter of this process is the LDL receptor (LDLR), which is strikingly efficient at
eliminating circulating LDL-C. Despite the proficiency of LDLRs the uptake of cholesterol is
carefully regulated by intracellular cholesterol levels (18). Changes in cellular levels of free
cholesterol (FC) provoke two major negative-feedback loops, the first of which acts on 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is the key rate limiting
enzyme in cholesterol biosynthesis  (18). The second negative feedback loop suppresses the
synthesis of LDLRs (18). Cholesterol entering the cell from the LDL particle also triggers the
cholesterol-esterifying enzyme, acyl CoA: cholesterol acyltransferase (ACAT). Esterification
of  cholesterol  by  ACAT2 converts  FC  to  cholesterol  esters,  which  in  a  hepatic  cell  are
incorporated  into  VLDL  and  returned  to  the  plasma  (18).  By  employing  these  key
mechanisms cellular cholesterol levels are subject to tight homeostatic regulation. However,
during ageing even the most tightly regulated biological systems are subject to disruption.
Due  to  the  complex  nature  of  ageing,  unravelling  the  mechanisms  which  underpin  the
impairment of a biological system such as cholesterol homeostasis is challenging. However,
it can be argued the free radical theory of ageing (FRTA) is the closest gerontology has come
to providing a framework which accounts for the systemic impact of ageing on biological
systems.  The theory  was proposed by Harman in 1956,  who postulated ageing could be
viewed as the result of the accumulation of free radical damage (19). Harman subsequently
adapted the theory to suggest free radicals leaking from the mitochondria electron transport
chain where the key drivers of ageing (20). This theory has evolved further over the years and
is now defined with respect to oxidative stress (21). According to the modern interpretation of
the theory, reactive oxidative species (ROS) are usually maintained at low levels within the
cell (21). Maintenance of ROS levels is achieved by a subtle balancing act between the rate
of production and the rate of scavenging by a plethora of antioxidant systems (22, 23). Thus,
the contemporary version of the free radical theory suggests ageing results from a decline in
the antioxidative capacity of the cell coupled with a concomitant increase in pro-oxidative
processes. 
Hypothesis
It is possible to adopt the contemporary version of the FRTA together with the cholesterol
homeostasis paradigm to introduce a hypothesis which accounts for the impact of intrinsic
ageing on LDL-C levels in older people. The key elements of this hypothesis are illustrated in
figure 2. It is our conjecture, cholesterol biosynthesis in older people is underscored by two
different metabolic states. In the first metabolic state hepatic endogenous antioxidant capacity
is  insufficient  to  deal  with  increased  ROS  levels.  The  metabolic  consequences  of  this
deficiency are that ROS induce the total activation of HMG-CoA reductase, which increases
the production of hepatic FC. This elicits a corresponding rise in plasma LDL-C due to the
increased secretion of  VLDL-C. Such individuals are  at  risk of developing CVD via the
atherosclerosis  model  outlined  previously.  In  the  second  scenario  which  accounts  for
cholesterol  metabolism  in  very  old  people,  endogenous  antioxidant  capacity  is  also
overwhelmed by rising intracellular ROS levels. This results in the total activation of HMG-
CoA reductase; however, the defining feature of this situation is the low activity of ACAT2.
The low activity  of ACAT2 causes a  reduction in the secretion of VLDL-C leading to  a
decrease in LDL-C production. In our opinion, this metabolic scenario is equally deleterious,
because despite a drop in plasma LDL-C levels, intracellular levels of FC accumulate. The
build-up  of  hepatic  FC  could  contribute  to  the  progression  of  a  condition  a-kin  to
nonalcoholic fatty liver disease (NAFLD). NAFLD is associated with an increased risk of
developing CVD (24). It is our conjecture that the inverse relationship between the risk of
CVD mortality and LDL-C that has been observed in the oldest old can be accounted for by
this  pernicious  metabolic  state,  which  is  summarised as  follows:  Age  related diminished
hepatic  antioxidant  capacity   increased ROS   total  activation of  HMG-CoA + drop in
ACAT2  activity reduced  secretion  of  VLDL-C   a  drop  in  LDL-C  production  with
concomitant increase in hepatic FCpathophysiological condition akin to NAFLD.   
Hypothesis evaluation
It is cogent to evaluate the evidence both for and against the arguments outlined above.  A
central challenge to our hypothesis is the FRTA remains controversial. This is emphasized by
experimental  findings  from  a  broad  range  of  organisms  over  the  last  few  decades
contradicting  and  supporting  the  FRTA  (25).  Therefore,  if  the  claim  hepatic  antioxidant
capacity  decreases  with  age  is  examined,  the  literature  is  to  an  extent  conflicting  and
inconclusive. For instance, key studies support this idea, such as Semsei et al (1989) who
found activities of superoxide dismutase (SOD) and catalase decreased significantly with age
in rat liver (26); and Ji (1993) who observed that SOD and glutathione S-transferase activities
were significantly decreased in old rodents (27). Juxtapositioned with the idea of diminished
antioxidant capacity is the conjecture, ageing is associated with increased ROS production by
hepatic  mitochondria. This  part  of  the  hypothesis  is  supported  by  studies,  such  as  that
conducted by Sawada et al. (1987) which identified considerable increases in hepatic lipid
peroxidation oxidization in the liver of ageing rats (28). Conversely, a significant number of
studies have found that endogenous antioxidants and rates of mitochondrial ROS production
are low in long-lived animals (29). The proposed biological explanation for this, is that mild
mitochondrial oxidative stress render the cell less vulnerable to subsequent oxidative assaults
in a process known as mitohormesis (30). 
If  the  idea  is  examined that  ROS are  responsible  for  the  total  activation  of  HMG-CoA
reductase,  evidence for this is sparse but compelling. Pallottini  and co-workers suggested
ROS have a role to play in the age-related dysregulation of HMG-CoA reductase related to
hypercholesterolemia in rats (31). Pallottini et al. (2006) also showed ROS impacted HMG-
CoA reductase activity in thioacetamide-induced liver injury in rats (32). This group further
demonstrated  ROS levels  influence  HMG-CoA reductase  dephosphorylation  in  aged rats
(33). Collectively, these results do support the notion that ROS have a significant impact on
cholesterol biosynthesis. However, a caveat does exists as ROS may not be the main driver of
HMG-CoA reductase activation in females. A study by Trapani et al. (2010) using estropausal
rats  found  that  estrogen  deficiency  in  female  rats  was  correlated  with  higher  HMGR
activation and did not depend on a rise in ROS, as previously observed in aged-match male
rats  (34).  The authors  postulated that  lower levels  of  AMP-activated protein  kinase  as  a
consequence  of  estrogen deficiency was responsible  for  provoking a  decrease  in  HMGR
phosphorylation and subsequent enzyme activation. This is perhaps not surprising as it is
known that cholesterol metabolism is intimately connected to hormonal regulation (35). The
authors also proposed that several different mechanisms drive dyslipidemia in older men and
women (36). However, it can be broadly concluded that ROS have the potential to unregulate
HMG-CoA.   Explaining  why  ROS  have  such  a  profound  effect  on  this  key  enzyme  is
challenging.  One  interesting  explanation  from an  evolutionary  perspective  is  that  sterols
played a  protective  role  against  oxidative  stress  in  early  eukaryote  cells  (37).  Thus,  the
upregulation of HMGR could be part of an early regulatory mechanism which evolved to
protect the cell from increasing levels of oxidation. 
The  next  assertion  requiring  inspection,  is  the  proposed age-related reduction  in  ACAT2
activity  and  its  association  with  both  reduced VLDL-C and LDL-C levels.  This  idea  is
tentatively  supported  by  Shiomi  et  al  (2000)  who  examined  cholesterol  metabolism  in
homozygous Watanabe heritable hyperlipidemic rabbits  (38); an animal model deficient in
LDLRs.  Despite  this  deficiency,  these  rabbits  display  a  considerable  decrease  in  in  total
plasma cholesterol and LDL-C with age. Shiomi and colleagues identified that a decrease in
ACAT activity together with a reduction in the secretion rate of VLDL-C, could account for
an age related decrease in LDL-C. 
According to our hypothesis, a decrease in ACAT activity should also correspond with the
accumulation of hepatic FC leading to a condition akin to NAFLD. Notably, it has found
been  that hepatic FC accumulates  in both NAFLD and nonalcoholic steatohepatitis  (39).
Moreover, Min et al (2012) reported increased cholesterol biosynthesis in NAFLD subjects
(40). However, it was also found that cholesterol ester hydrolase increased, ACAT2 levels
remained unchanged, and LDLR expression reduced significantly.  The fact ACAT2 levels
were unchanged is not overly significant for our hypothesis as the mean age of the subjects in
this study was 42.5 ± 7.5 years and our conjecture is that this enzyme increases significantly
in  older  age.  As  would  be  expected  in  a  study  of  this  nature,  HMGCR expression  was
correlated with FC, while LDL-C levels varied directly with HMGCR and inversely with
LDLR expression in these patients. 
The  final  aspect  of  our  hypothesis  requiring  examination  is  the  counter  thesis  to  our
standpoint,  that  both  high  and  low  LDL-C  levels  can  present  a  significant  risk  to
cardiovascular  health  in  older  people.  Interestingly,  despite  decades  of  overwhelming
evidence  to  the  contrary recent  efforts  have  been made  to  establish  a  case  that  elevated
plasma cholesterol levels do not present a meaningful risk to cardiovascular health (41, 42).
Thus,  an  imperative  exists  to  examine  this  claim,  as  both  a  counter  argument  to  our
hypothesis and because of its challenge to scientific orthodoxy within the field of cholesterol
metabolism.  The  attraction  to  this  controversial  and  unconventional  idea  is  somewhat
understandable  due  to  some  intriguing  findings  in  lipid  metabolism over  the  years.  For
example, it has been suggested lipoproteins offer a degree of protection from inflammation,
possibly  by  increasing  the  effectiveness  of  the  immune  system  via  a  redistribution  of
cholesterol/ triglycerides to immune cells (43). Another potential avenue which could be used
to infer a positive role for high plasma cholesterol levels is the proposal that cholesterol is a
circulatory antioxidant. This idea was originally proposed by Smith (1991) who suggested the
presence of oxidized oxysterols of human blood represent past  interception of blood and
tissue oxidants in vivo by cholesterol as a key component of oxygen metabolism (44). This
idea also conveniently dovetails with the hypothesis that an early evolutionary role for sterols
was in protecting the cell from increasing levels of oxygen. Thus, within such a framework,
an altruistic role for cholesterol could be constructed to account for low levels of LDL-C and
increased CVD risk. However, given the overwhelming evidence correlating elevated plasma
LDL-C levels with atherosclerosis, the suggestion LDL-C is protective appears to be remote. 
Investigating the hypothesis 
It would be worthwhile exploring the ideas outlined in this paper in greater depth. However, a
significant  obstacle  to  this  is  that  the  human  liver  is  subject  to  a  multitude  of  dynamic
processes. Recently, ageing research and lipid metabolism have benefited from adopting the
systems  biology  paradigm  (45-48).  This  framework  provides  a  means  of  handling  the
complexities of hepatic cholesterol metabolism and ageing. Key to this approach is the use of
mathematical models which enable the integration of disparate experimental data  (49-52).
This approach overcomes many of the challenges associated with investigating hepatic lipid
metabolism and provides an excellent framework for hypothesis exploration. 
Consequences of the hypothesis and discussion 
Elevated plasma levels of LDL-C are the gold standard risk factor for CVD. However, in
older people LDL-C levels can decrease, and in some instances are inversely associated with
risk of cardiovascular mortality.  It is not known why this happens, however this paradox
could  mask  an  underlying  disease.  Future  investigations  which  examine  cholesterol
metabolism in the oldest old should give careful consideration to exploring the relationship
between LDL-C levels, and conditions such as NAFLD in this population group. Moreover,
based on the hypothesis outlined in this paper it is possible extremely low levels of LDL-C
could  be  used  as  a  surrogate  marker  of  hepatic  pathology  in  older  people.  Further
investigations  also  need to  be  conducted  into  the  activity  of  ACAT2 in  humans  and  its
potential  decline during ageing. In  particular,  it  would be worthwhile  investigating if  the
activity  of  ACAT2 is  also  susceptible  to  ROS.  This  would provide  a  mechanism for  its
dysregulation and help to explain why certain middle aged people have normal/high levels of
LDL-C which gradually decrease with age. 
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Figure 1. An example of how LDL-C rises to the midpoint of life and then declines in later years 
in the US population (Data taken from reference 5).  
Figure 2. Diagrammatic representation of the intersection of the FRTA with Cholesterol 
homeostasis. Based on our hypothesis a decrease in hepatic antioxidant capacity and a rise in 
ROS provokes increased cholesterol biosynthesis, which increases LDL-C. Conversely when an 
increase in ROS is accompanied by a decline in the activity of ACAT2 this results in decreased 
LDL-C with a concomitant increase in hepatic FC. 
